• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 SARS-CoV-2 细胞介导免疫反应的干扰素γ释放分析(IGRA)的诊断性能。

Diagnostic Performance of Interferon Gamma Release Assay (IGRA) for Cell-Mediated Immune Responses to SARS-CoV-2.

出版信息

Clin Lab. 2023 Mar 1;69(3). doi: 10.7754/Clin.Lab.2022.220643.

DOI:10.7754/Clin.Lab.2022.220643
PMID:36912314
Abstract

BACKGROUND

As SARS-CoV-2 infection became a pandemic, much effort has been made to measure both antibody production and T cell response to SARS-CoV-2 to diagnose COVID-19 patients or find out their immune status. Authors tried to determine the optimal cutoff value and evaluate clinical performance of one interferon-γ release assay (IGRA) kit and compared their results with serological antibody assay in COVID-19 patients.

METHODS

Study subjects included 100 patients confirmed as COVID-19 with RT-PCR method and 88 healthy volunteers who were PCR negative. IGRA tests were performed using STANDARDTM E Covi-FERON ELISA. Presence of SARS-CoV-2 antibodies was detected using STANDARD Q COVID-19 IgM/IgG Plus Test. Cutoff value was assessed using receiver operating characteristic (ROC) curve.

RESULTS

The cutoff value was 0.24 IU/mL and the area under the curve (AUC) of the ROC curve was 0.973 with 95% confidence interval (CI) of 0.940 - 1.005. At this cutoff value, sensitivity and specificity were 91.7% and 100%, respectively. In addition, when compared with antibody test, concordance rate was 95%.

CONCLUSIONS

STANDARDTM E Covi-FERON ELISA showed high sensitivity and specificity, when the cutoff value was 0.24 IU/mL. It was also consistent with the antibody test. IGRA test was a good indicator of cellular immune response in COVID-19 patients.

摘要

背景

随着 SARS-CoV-2 感染成为大流行,人们做出了很大努力来测量 SARS-CoV-2 的抗体产生和 T 细胞反应,以诊断 COVID-19 患者或了解其免疫状态。作者试图确定一种干扰素-γ释放测定(IGRA)试剂盒的最佳截断值,并评估其在 COVID-19 患者中的临床性能,并将其结果与血清学抗体检测进行比较。

方法

研究对象包括 100 名经 RT-PCR 方法确诊为 COVID-19 的患者和 88 名 PCR 阴性的健康志愿者。使用 STANDARDTM E Covi-FERON ELISA 进行 IGRA 检测。使用 STANDARD Q COVID-19 IgM/IgG Plus Test 检测 SARS-CoV-2 抗体的存在。使用接收者操作特征(ROC)曲线评估截断值。

结果

截断值为 0.24IU/ml,ROC 曲线下面积(AUC)为 0.973,95%置信区间(CI)为 0.940-1.005。在该截断值下,敏感性和特异性分别为 91.7%和 100%。此外,与抗体检测相比,一致性率为 95%。

结论

当截断值为 0.24IU/ml 时,STANDARDTM E Covi-FERON ELISA 显示出较高的敏感性和特异性。它也与抗体检测一致。IGRA 检测是 COVID-19 患者细胞免疫反应的良好指标。

相似文献

1
Diagnostic Performance of Interferon Gamma Release Assay (IGRA) for Cell-Mediated Immune Responses to SARS-CoV-2.基于 SARS-CoV-2 细胞介导免疫反应的干扰素γ释放分析(IGRA)的诊断性能。
Clin Lab. 2023 Mar 1;69(3). doi: 10.7754/Clin.Lab.2022.220643.
2
Comparative analysis between STANDARD-E Covi-FERON ELISA with pre-existing IFN-γ release assays and determination of the optimum cutoff value for assessment of T-Cell response to SARS-CoV-2.STANDARD-E Covi-FERON ELISA 与现有 IFN-γ 释放检测方法的比较分析,以及评估 SARS-CoV-2 特异性 T 细胞反应的最佳截断值的确定。
J Clin Lab Anal. 2023 Mar;37(6):e24882. doi: 10.1002/jcla.24882. Epub 2023 Apr 9.
3
Long-Term Accuracy of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay and Its Application in Household Investigation.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)干扰素-γ释放试验的长期准确性及其在家庭调查中的应用
Clin Infect Dis. 2022 Aug 24;75(1):e314-e321. doi: 10.1093/cid/ciac045.
4
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination.一种标准化严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)干扰素-γ释放检测试剂盒的临床性能,用于简单检测感染或接种疫苗后的 T 细胞反应。
Clin Infect Dis. 2022 Aug 24;75(1):e338-e346. doi: 10.1093/cid/ciab1021.
5
A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort.一项评估干扰素γ释放试验(IGRA)的初步研究,以测量在一个独特的与世隔绝队列中 COVID-19 感染或接种疫苗后 T 细胞免疫反应。
J Clin Microbiol. 2022 Mar 16;60(3):e0219921. doi: 10.1128/jcm.02199-21. Epub 2022 Jan 12.
6
Integrating SARS-CoV-2-specific interferon-γ release assay testing in the evaluation of patients hospitalized with COVID-19.将 SARS-CoV-2 特异性干扰素-γ 释放试验检测整合到 COVID-19 住院患者的评估中。
Microbiol Spectr. 2023 Dec 12;11(6):e0241923. doi: 10.1128/spectrum.02419-23. Epub 2023 Oct 19.
7
Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay.在厄瓜多尔未接触过 SARS-CoV-2 的健康对照者中,使用 COVID-19 干扰素释放分析检测到预先存在的针对 SARS-CoV-2 的 T 细胞免疫。
Int J Infect Dis. 2021 Apr;105:21-25. doi: 10.1016/j.ijid.2021.02.034. Epub 2021 Feb 12.
8
Clinical diagnostic performance evaluation of five immunoassays for antibodies to SARS-CoV-2 diagnosis in a real-life routine care setting.五种用于 SARS-CoV-2 抗体诊断的免疫分析方法在真实临床常规检测环境中的临床诊断性能评估。
Pan Afr Med J. 2021 May 3;39:3. doi: 10.11604/pamj.2021.39.3.26471. eCollection 2021.
9
Analysis of Nucleic Acid and Antibody Detection Results for SARS-CoV-2 Infection.分析 SARS-CoV-2 感染的核酸和抗体检测结果。
Arch Iran Med. 2021 May 1;24(5):427-433. doi: 10.34172/aim.2021.61.
10
An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses.评估 FluoroSpot assay 作为一种诊断工具,以确定 SARS-CoV-2 特异性 T 细胞反应。
PLoS One. 2021 Sep 30;16(9):e0258041. doi: 10.1371/journal.pone.0258041. eCollection 2021.

引用本文的文献

1
Application of Interferon-γ Release Assay in the Assessment of T-Cell Immunity to SARS-CoV-2 Antigens in the Cohort of Pediatric Patients with Juvenile Idiopathic Arthritis.干扰素-γ释放试验在幼年特发性关节炎患儿队列中评估针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗原的T细胞免疫方面的应用
Children (Basel). 2024 Jun 16;11(6):736. doi: 10.3390/children11060736.
2
Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.利妥昔单抗治疗的风湿患者在接种 SARS-CoV-2 疫苗后持续的细胞介导而不是体液反应。
Rheumatology (Oxford). 2024 Feb 1;63(2):534-541. doi: 10.1093/rheumatology/kead236.